In this article

BMY

JNJ

Follow your favorite stocks CREATE FREE ACCOUNT

Johnson & Johnson said on Wednesday its experimental psoriasis drug has shown superior skin clearance compared to Bristol Myers Squibb's Sotyktu in two late-stage head-to-head trials.

J&J has been working on more convenient treatment options for psoriasis as its injectable drug Stelara, which recorded over $10 billion in sales last year, faces stiff competition from cheaper rivals.

The drugmaker said its oral pill, icotrokinra, met both main and secondary goals when compared to placebo and Bristol's Sotyktu at weeks 16 and 24 in adult patients in the trials.

Icotrokinra also showed similar adverse event rates to placebo with no new safety signals.

Bristol's Sotyktu is already approved to tre

See Full Page